Vertex Pharmaceuticals (VRTX) recently announced that it has agreed to acquire Crinetics (CRNX) for $10 billion in cash, marking the largest transaction in the company’s history and signaling its formal entry into the field of endocrinology. Under the terms of the agreement, the $85-per-share purchase price represents a premium of as much as 102% over Crinetics’ Monday closing price. After deducting Crinetics’ cash on hand, the transaction’s effective valuation stands at approximately $8.8 billion, and it is expected to bolster Vertex’s adjusted operating revenue for 2029. The acquisition has received approval from the boards of both companies and is scheduled to close within the third quarter. Bolstered by the news, Crinetics’ shares doubled in price after regular trading on Monday, while Vertex shares fell 2% in after-hours trading.
The core asset of this acquisition is an investigational once-daily oral drug developed by Crinetics, designated Palsonify, which is being developed for a rare pituitary disorder. In addition, Crinetics is also developing novel therapies for congenital adrenal hyperplasia, a genetic condition. Vertex projects that these two products could collectively contribute more than $5 billion in annual revenue at their peak sales phases.
As the undisputed leader in the cystic fibrosis treatment space, Vertex generated $10.3 billion in revenue last year from its blockbuster drug Trikafta, which accounted for 85% of the company’s total revenue. However, in other disease areas, the company has yet to replicate a similar level of impact. Its approved gene-editing therapy Casgevy (for sickle cell disease and beta-thalassemia) has seen slow commercial uptake, and its novel non-opioid analgesic Journavx remains in the early stages of market introduction. BMO Capital Markets analyst Evan David Seigerman expressed approval of the deal, noting that it helps Vertex broaden its rare disease product portfolio and positions it for direct competition with Neurocrine Biosciences and its endocrine drugs. To fund this massive transaction, Vertex will utilize its own cash reserves and rely on $4.5 billion in bridge financing from Bank of America and Morgan Stanley.
Although Vertex’s stock has risen approximately 17% year-to-date, outperforming the S&P 500’s roughly 10% gain over the same period and repeatedly hitting all-time highs, the company’s recent financial performance has not been particularly outstanding. Its quarterly report for the period ended March 31 showed that sales grew only 8% to approximately $3 billion, with overall growth rates showing a deceleration trend in recent years. Market confidence in the company’s future growth primarily hinges on the subsequent commercial rollout of Casgevy and Journavx, as well as potential breakthroughs across multiple pipeline candidates. However, from a valuation perspective, Vertex’s current price-to-earnings ratio of approximately 31 times (based on trailing 12-month earnings) stands notably above the S&P 500 average of 25 times, while its PEG (price/earnings-to-growth) ratio, which reflects future growth expectations, stands at about 2.0, far exceeding the reasonable buy threshold of 1.0. The elevated valuation suggests that the current share price may have already fully priced in future growth prospects, leaving both upside potential and downside risk coexisting going forward.
